Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Inclusion Criteria: * 18 years of age or older * Endometrial cancer * Patients must have been treated with at least one line of chemotherapy, but not more than two lines of chemotherapy, and experienced progressive disease * At least one measurable lesion * ECOG performance status less than or equal to 1 * Minimum life expectancy of 3 months * Adequate renal and hepatic function * Adequate bone marrow function * Serum cholesterol \<350 mg/dL and triglycerides \< 400 mg/dL * Able to understand and give written informed consent * Females of childbearing potential must have a negative pregnancy test and use approved contraception from screening to 30 days after the last study drug is given Exclusion Criteria: * Two lines of chemotherapy for recurrent or metastatic disease * Chemotherapy for recurrent or metastatic disease administered within six months of adjuvant therapy * More than two lines of chemotherapy of any type * Prior therapy with hormonal agents * Women who are pregnant or lactating * Presence of brain or other central nervous system metastases * Prior therapy with rapamycin, rapamycin analogues or tacrolimus or known sensitivity to these agents * Anticancer treatment (chemotherapy, radiotherapy) within 4 weeks prior to randomization * Ongoing toxicity associated with prior anticancer therapy * Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to randomization. * Another primary malignancy within the past five years (except for non-melanoma skin cancer and cervical carcinoma in situ) * Known Grade 3 or 4 hypersensitivity to macrolide antibiotics * Significant uncontrolled cardiovascular disease * Active infection * Known HIV infection * Known Hepatitis B or C infection * Newly diagnosed (within 3 months before enrollment) or poorly controlled Type 1 or 2 diabetes * Concurrent treatment with immunosuppressive agents * A requirement for concurrent treatment with medication that strongly induce or inhibit cytochrome P450 (CYP3A)